KZIA | Kazia Therapeutics Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.50 - 6.01
52 Week Range	1.9000 - 15.80
Beta	1.93
Implied Volatility	363.63%
IV Rank	4.22%
Day's Volume	41,004
Average Volume	146,515
Shares Outstanding	2,961,264
Market Cap	16,612,691
Sector	Healthcare
Industry	Biotechnology
IPO Date	1999-01-06

Valuation
Profitability
Growth
Health
P/E Ratio	-0.85
Forward P/E Ratio	N/A
EPS	-6.57
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	Australia
Website	KZIA

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

KZIA's peers: CTMX, ASMB, OCUL, SPRO, ACHL, SLS, NLSP, MREO, ARAV, DAWN, ZIVO, RNXT, KTTA, QNRX, ABIO, BNOEF, OKYO, CADL, ANEB, CINGW, NRIX, SEER, QSI, HCWB, MNOV

*Chart delayed

Analyzing fundamentals for KZIA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see KZIA Fundamentals page.

Watching at KZIA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on KZIA Technicals page.